论文信息 - First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response - 字舞流文

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

G. Gibney | T. Seiwert | M. Callahan | K. Papadopoulos | S. Kummar | T. Yap | O. Rahma | G. Falchook | H. Cohen | S. Tykodi | J. Gainor | H. Laken | M. Fan | R. Pachynski | Haeseong Park | M. B. Blum Murphy | A. Sepahi | Christopher J Harvey | H. Burris | Yasmin Hashambhoy-Ramsay | E. Trehu | P. Lorusso | A. Hanson | Richard Murray | L. McGrath | J. Baeck | C. Hart | P. LoRusso | E. Hooper | Xiaoying Xiao | Daniel Felitsky | Rachel McComb | K. Brown | J. Jimenez | Weidong Zhang